TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19949851

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted behavioral treatment with Internet-based client-therapist contact
Number of subjects: 19

Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 19
Study: 19067501

Group type: EXPERIMENTAL
Intervention: ScriptAssist telehealth nursing program using psychological techniques, average of 3.5 calls over 9 months.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: ScriptAssist telehealth nursing program using psychological techniques.
Number of subjects: 51
Study: 16897917

Group type: EXPERIMENTAL
Intervention: Standard Revised Conflict Tactics Scales (CTS2) categories
Number of subjects: 160

Group type: COMPARATOR
Intervention: Dichotomous (yes/no) response categories
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Computer administrations
Number of subjects: 160

Group type: COMPARATOR
Intervention: Paper‐and‐pencil administrations
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sexual coercion rates
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 160
Study: 12814227

Group type: EXPERIMENTAL
Intervention: System B HeatSource fitted with a medium plugger at a temperature of 225 degrees C for 5 s on buccal and 5 s on lingual (Group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: System B HeatSource fitted with a medium plugger at a temperature of 225 degrees C for 8 s on buccal and 8 s on lingual (Group 2)
Number of subjects: 20
Study: 10653831

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8842352

Group type: EXPERIMENTAL
Intervention: Apo E4 allele carriers (n = 71)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Apo E4 allele carriers with ACE D allele (n = 55)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Apo E4 and ACE D allele carriers
Number of subjects: 231
Study: 1635534

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 39
Study: 6477792

Group type: EXPERIMENTAL
Intervention: Metoclopramide i.v.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Narcotics during established labour
Number of subjects: 120
Study: 31136218

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (speed endurance training, SET; n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual lifestyle (control group; n = 10)
Number of subjects: 20
Study: 28351689

Group type: EXPERIMENTAL
Intervention: Study-specific HIV algorithm using simple/rapid tests (SRTs)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Gold standard testing algorithm
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combined antigen/antibody and single antigen tests
Number of subjects: 61
Study: 27603149

Group type: EXPERIMENTAL
Intervention: Antiviral agents along with Korean Red Ginseng powder capsules (1 gram per dose, 3 grams per day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Antiviral agents alone
Number of subjects: 38
Study: 24811049

Group type: EXPERIMENTAL
Intervention: Sun protection message that primed mortality and UV-filtered photo of their face
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reminders of mortality with UV photo framed as revealing appearance consequences of tanning
Number of subjects: 0
Study: 22017999

Group type: EXPERIMENTAL
Intervention: Intervention C (personalised goal setting, 'cook and eat', and education)
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Intervention C
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Socially deprived participants (n 119)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Intervention A (education only)
Number of subjects: 589

Group type: COMPARATOR
Intervention: Intervention B ('cook and eat' sessions only)
Number of subjects: 589
Study: 19382496

Group type: EXPERIMENTAL
Intervention: EPs 7630, a herbal drug preparation from the roots of Pelargonium sidoides, 60 drops three times daily for maximum 22 days
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 17688460

Group type: EXPERIMENTAL
Intervention: Adjunctive therapy combining lithium or valproate with olanzapine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adjunctive therapy combining lithium or valproate with risperidone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adjunctive therapy combining lithium or valproate with haloperidol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adjunctive therapy combining lithium or valproate with quetiapine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monotherapy with agents like olanzapine, risperidone, haloperidol, or quetiapine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination therapies
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 100
Study: 15481160

Group type: EXPERIMENTAL
Intervention: Topical IFN-alpha treatment for two weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Allergen challenge
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 6
Study: 11156811

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 9489823

Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin at 6, 12, 50, 100, and 200 microg/kg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7817528

Group type: EXPERIMENTAL
Intervention: Test diet (food fiber 55 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine diet (food fiber 25 g/day)
Number of subjects: 0
Study: 2847348

Group type: EXPERIMENTAL
Intervention: LMWH-DHE (1,500 U anti-Xa of LMWH + 0.5 mg DHE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (5,000 IU)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study: 30168896

Group type: EXPERIMENTAL
Intervention: ASI 500 U
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA 500 U
Number of subjects: 369

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 369
Study: 29073629

Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure reduction (target systolic BP <140 mm Hg)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Contemporaneous guideline-recommended BP lowering
Number of subjects: 404
Study: 24909188

Group type: EXPERIMENTAL
Intervention: Topical glycopyrrolate (2%)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 23794519

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion
Number of subjects: 115

Group type: COMPARATOR
Intervention: Pharmacological cardioversion
Number of subjects: 115
Study: 22146253

Group type: EXPERIMENTAL
Intervention: Dentist-manipulated border-molding technique
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patient-manipulated border-molding technique
Number of subjects: 36
Study: 20029516

Group type: EXPERIMENTAL
Intervention: Thermogenic product (TP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 16969659

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (100 mJ/pulse, 10 Hz)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mechanical debridement with plastic curettes and antiseptic therapy (chlorhexidine digluconate 0.2%)
Number of subjects: 20
Study: 16304572

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (allo-BMT) after four blocks of intensive chemotherapy
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplant (A-BMT) after four blocks of intensive chemotherapy
Number of subjects: 758

Group type: COMPARATOR
Intervention: Four blocks of treatment
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Five blocks of treatment
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: MRC AML 12
Number of subjects: 758

Group type: COMPARATOR
Intervention: MRC AML 10
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Short course of triple intrathecal chemotherapy for CNS-directed treatment
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Improvements in supportive care
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Current MRC AML 15 trial
Number of subjects: 758

Group type: COMPARATOR
Intervention: Standard MRC anthracycline-based consolidation
Number of subjects: 758
Study: 11915005

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir
Number of subjects: 0
Study: 9445329

Group type: EXPERIMENTAL
Intervention: Stroke unit (n=364)
Number of subjects: 802

Group type: COMPARATOR
Intervention: General medical ward (n=438)
Number of subjects: 802
Study: 8719697

Group type: EXPERIMENTAL
Intervention: Disodium fluorescein (DSF)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Carboxyfluorescein (CF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: N/A (Control group: Normal subjects)
Number of subjects: 26
Study: 2718918

Group type: EXPERIMENTAL
Intervention: Estrogen-containing oral contraceptives (OCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (1700 micrograms vitamin A per capsule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplement (68,000 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (intrauterine contraceptive device (IUCD) users)
Number of subjects: 0
Study: 822857

Group type: EXPERIMENTAL
Intervention: Imipramine (3 X 50 mg/day) + Thyrotrophin releasing hormone (TRH) (2 X 40 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Imipramine (3 X 50 mg/day) + Placebo
Number of subjects: 30
Study: 31624297

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU vitamin D3 fortnightly for 4 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (pearl fortnightly for 4 months)
Number of subjects: 44
Study: 26703981

Group type: EXPERIMENTAL
Intervention: Regular coffee (450 mg/d caffeine content)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (12 mg/d caffeine content)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Previous low coffee users
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Previous frequent coffee users
Number of subjects: 49
Study: 26416895

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (GCSF) - filgrastim for 7 days or pegfilgrastim
Number of subjects: 407

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (GCSF)
Number of subjects: 407
Study: 23504814

Group type: EXPERIMENTAL
Intervention: Polymethylpentane (PMP) oxygenator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Polypropylene (PPL) oxygenator
Number of subjects: 20
Study: 21523716

Group type: EXPERIMENTAL
Intervention: Docetaxel (35 mg/m² on days 1 and 8) plus S-1 (35 mg/m² each twice daily on days 1-14)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin (35 mg/m² each on days 1 and 8)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Docetaxel plus S-1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SPARC expression
Number of subjects: 80
Study: 19397185

Group type: EXPERIMENTAL
Intervention: Oportunidades program (conditional cash-transfer program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oportunidades program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oportunidades program and Control group
Number of subjects: 0
Study: 16713529

Group type: EXPERIMENTAL
Intervention: Adherence self‐report tool
Number of subjects: 245

Group type: COMPARATOR
Intervention: Electronic monitoring
Number of subjects: 245
Study: 15461603

Group type: EXPERIMENTAL
Intervention: drugs + SLIT
Number of subjects: 511

Group type: COMPARATOR
Intervention: drugs only
Number of subjects: 511
Study: 11146520

Group type: EXPERIMENTAL
Intervention: Abciximab Group (37 patients)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Non-Abciximab Group (47 patients)
Number of subjects: 84
Study: 9388805

Group type: EXPERIMENTAL
Intervention: Consistent information exposure
Number of subjects: 190

Group type: COMPARATOR
Intervention: Misleading information exposure
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Explicit questioning
Number of subjects: 190

Group type: COMPARATOR
Intervention: Nonexplicit questioning
Number of subjects: 190
Study: 7929503

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.03 microgram per kilogram of body mass)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 3209626

Group type: EXPERIMENTAL
Intervention: Dispersible tablets of levodopa-benserazide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard capsule of levodopa-benserazide
Number of subjects: 16
Study: 28902028

Group type: EXPERIMENTAL
Intervention: A-101 40%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A-101 32.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle solution
Number of subjects: 0
Study: 28618234

Group type: EXPERIMENTAL
Intervention: Aloe vera 3% ointment, 1 g twice daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo ointment, 1 g twice daily for 4 weeks
Number of subjects: 20
Study: 25141922

Group type: EXPERIMENTAL
Intervention: Ketamine (100 ng/ml)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 19
Study: 23269816

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) emulsion, 0.2 g/kg, 3 infusions before and after surgery
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 28
Study: 21194588

Group type: EXPERIMENTAL
Intervention: Enzymatic cleanser solution (Polident 3 Minutes)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cleanser solution (Corega Tabs)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite (NaOCl) solution
Number of subjects: 116

Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 116
Study: 18300086

Group type: EXPERIMENTAL
Intervention: Home-based pencil push-ups
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Home-based computer vergence/accommodative therapy and pencil push-ups
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy with home reinforcement
Number of subjects: 221

Group type: COMPARATOR
Intervention: Office-based placebo therapy
Number of subjects: 221
Study: 16226901

Group type: EXPERIMENTAL
Intervention: Polidocanol foam
Number of subjects: 75

Group type: COMPARATOR
Intervention: Liquid polidocanol
Number of subjects: 75
Study: 12633635

Group type: EXPERIMENTAL
Intervention: Atrial septal pacing
Number of subjects: 17

Group type: COMPARATOR
Intervention: Combined pacing algorithm (atrial pacing preference; atrial rate stabilization; and post mode-switch overdrive pacing) in AT500 pacemakers
Number of subjects: 17

Group type: COMPARATOR
Intervention: Atrial pacing preference activated in Pulsar Max group
Number of subjects: 17
Study: 10883554

Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Benzodiazepine
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 50
Study: 9218088

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg isosorbide dinitrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1382879

Group type: COMPARATOR
Intervention: 1 mg.kg‐1 meperidine (Group 1, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 meperidine plus 0.5 mg.kg‐1 prilocaine (Group 2, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 meperidine plus 0.5 mg.kg‐1 prilocaine (Group 2)
Number of subjects: 60
Study: 2856710

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clonidine (0.25 mg once daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily) + Clonidine (0.25 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30888598

Group type: EXPERIMENTAL
Intervention: EGFR Tyrosine Kinase Inhibitors (TKIs)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sequential treatment with EGFR TKIs followed by Crizotinib
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EGFR/ALK co-altered patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: EGFR-mutant patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: ALK-rearranged patients
Number of subjects: 22
Study: 29695348

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) using multicatheter brachytherapy
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Whole-breast irradiation (50 Gy with a boost of 10 Gy)
Number of subjects: 1184
Study: 27537762

Group type: EXPERIMENTAL
Intervention: 0.2 mg oral clonidine followed by 0.2 mg/d transdermal clonidine patch
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 24882587

Group type: EXPERIMENTAL
Intervention: Postural restriction for 10 days after the modified Epley maneuver
Number of subjects: 78

Group type: COMPARATOR
Intervention: No positional restriction after the modified Epley maneuver
Number of subjects: 78
Study: 23144441

Group type: EXPERIMENTAL
Intervention: Passive catheter care station (HubScrub and DOCit)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Standard caps with sterile, conventional open lumen 3-way stopcock set
Number of subjects: 572
Study: 20189328

Group type: EXPERIMENTAL
Intervention: Radiofrequency applied to the anterior 1/3 of the inferior choncha
Number of subjects: 40

Group type: COMPARATOR
Intervention: Radiofrequency applied to the whole of the inferior choncha
Number of subjects: 40
Study: 17945318

Group type: EXPERIMENTAL
Intervention: Dried-bonito broth (DBB)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 16085581

Group type: EXPERIMENTAL
Intervention: GFADS and 2-compartment kinetic analysis
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2-compartment approach
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Quantitative dynamic (82)Rb PET
Number of subjects: 13
Study: 12071024

Group type: EXPERIMENTAL
Intervention: Chemotherapy (preoperative, postoperative, and pre- and postoperative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy (preoperative, postoperative, and pre- and postoperative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy combinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiochemotherapy vs. Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study: 11592543

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Saline infusion sonography (SIS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 40
Study: 9219702

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (radiotherapy: 18.5 Gy in five fractions of 3.7 Gy each; cisplatin: 80 mg/m² body surface area administered 0 to 2 days before radiotherapy)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 282

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 282
Study: 8388950

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 gm single dose)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Doxycycline (7-day course)
Number of subjects: 73
Study: 2953239

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study: 30287719

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 48
Study: 28414043

Group type: EXPERIMENTAL
Intervention: Oral methotrexate, 25 mg weekly
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral mycophenolate mofetil, 1 g twice daily
Number of subjects: 80
Study: 26590962

Group type: EXPERIMENTAL
Intervention: Intradiscal methylene blue injection (IMBI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intradiscal isotonic saline with lidocaine and contrast (Control)
Number of subjects: 0
Study: 23159208

Group type: EXPERIMENTAL
Intervention: CCTA with 30 mL of contrast media (CM) following 5 mL of CM at timing bolus
Number of subjects: 126

Group type: COMPARATOR
Intervention: CCTA with 50 mL of CM following 10 mL of CM at timing bolus
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CT number-controlling system using the simple equation for CCTA following 5 mL of CM at timing bolus
Number of subjects: 126
Study: 21437603

Group type: EXPERIMENTAL
Intervention: Tyrosine (150 mg kg body mass(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (500 mL flavoured sugar‐free drink)
Number of subjects: 8
Study: 18458357

Group type: COMPARATOR
Intervention: Caffeine 0 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine 800 mg
Number of subjects: 24
Study: 16772453

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 605

Group type: COMPARATOR
Intervention: Prudent Western diet
Number of subjects: 605
Study: 12480560

Group type: EXPERIMENTAL
Intervention: Rifaximin (1200 mg/day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Lactitol (60 g/day)
Number of subjects: 103
Study: 10986366

Group type: EXPERIMENTAL
Intervention: Learning count nouns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Learning facts
Number of subjects: 0
Study: 9196611

Group type: COMPARATOR
Intervention: recombinant human GH (hGH) therapy
Number of subjects: 165
Study: 1494071

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening (faecal occult blood screening)
Number of subjects: 140000
Study: 29171135

Group type: EXPERIMENTAL
Intervention: ActivPals intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 28213841

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0